Athira Pharma

08/21/2024

This Friday, join us at the Alzheimer's Association, Orange County Chapter Research Advances event bringing together caregivers, patients, families, researchers, and healthcare professionals to learn about the latest in and dementia research.

Thank you to the Alzheimer’s Association for hosting this informative event to drive and educate on global research initiatives - we’re honored to be a presenting sponsor supporting this cause.

Register at no cost: https://alzassociationoc.wixstudio.io/research-advances

08/20/2024

Our Phase 2/3 LIFT-AD Study is evaluating the safety and efficacy of for the treatment of mild-to-moderate Alzheimer’s disease. Hear more on our company progress from CEO Mark Litton, Ph.D. as we approach our topline data readout of the clinical trial.

Learn more about : https://bit.ly/3zmY3Ip

08/14/2024

The mild-to-moderate stage of disease is characterized by heightened cognitive and functional decline leading to loss of patient independence. Despite this being the most distressing stage for patients and loved ones, there are currently no approved therapies to slow neurodegeneration for this specific population.

Fosgonimeton has the potential to address the mild-to-moderate stage of by providing neuroprotection and neuronal restoration, potentially reversing neurodegenerative symptoms. Stay tuned as we report topline data from our Phase 2/3 LIFT-AD clinical trial evaluating in AD in September.

Learn more: https://bit.ly/48NcRwO

08/12/2024

With multiple key data readouts expected, the space is poised for significant developments in the second half of 2024. In her recent BioSpace article, Heather McKenzie summarizes the highly anticipated neurological disease data readouts, including our LIFT-AD Phase 2/3 topline results of as a potential differentiated Alzheimer’s treatment.

Access the full article:

After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and neurodegenerative disease spaces during the next six months.

08/07/2024

That’s a wrap on ! Thank you for joining our discussion of ’s neuroprotective preclinical activity in models.

See you next year!

07/25/2024

The mild-to-moderate stage of Alzheimer’s disease can be the most distressing and detrimental stage for patients, which is why disease-modifying treatments are pivotal to effectively tackle and potentially reverse neurodegeneration progression at this stage.

Hear from Dr. Anton Porsteinsson on the unmet need for new treatments to reduce patient burden below.

Listen to the full webinar on Alzheimer’s and the LIFT-AD clinical trial: https://bit.ly/3zrFW3O

07/16/2024

What’s at stake for us? Developing therapies to counteract progression of neurodegenerative diseases— our vision and mission.

President and CEO Mark Litton, Ph.D., sat down with Life Science Leader's Wayne Koberstein to highlight our approach, his experience leading the Athira team, our pipeline progress throughout the years and what’s to come.

https://bit.ly/4cO95W4

Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.

07/09/2024

The last patient has completed dosing in our Phase 2/3 LIFT-AD clinical trial evaluating in mild-to-moderate disease, with topline results anticipated by end of Q3 2024.

Read the full announcement: https://investors.athira.com/news-releases/news-release-details/athira-pharma-announces-last-patient-completed-lift-ad-clinical

07/03/2024

As scientific pioneers, we’re taking a new approach to tackling Alzheimer's disease.

Our small molecules are designed to restore neuronal health by enhancing the naturally occurring neurotrophic HGF system. Listen to CEO Mark Litton, Ph.D. explain fosgonimeton’s mechanism of action in a recent conversation with Precision AQ:

06/27/2024

Pride creates a space of reflection, solidarity, empowerment and joy. As we wrap up month, join us in recognizing the impact of pride in fostering an inclusive and supportive environment promoting diversity, equity, and support, which we aim to nurture at Athira.

06/25/2024

This Alzheimer’s and Brain Awareness Month, we’re honored to join the conversations bringing awareness, understanding and support for the community and their loved ones. Hear from our CMO Javier San Martin, M.D. about how we’re addressing the unmet need for new, effective therapies for mild-to-moderate and advanced Alzheimer’s patients.

06/21/2024

Today we join the International Alliance of ALS/MND Associations in celebrating a global day of recognition and awareness for ALS/MND disease.

A progressive neurodegenerative disorder, leads to loss of muscle movement, eventual paralysis, and can be fatal. At Athira, we are advancing our investigational ALS treatment, ATH-1105, for the potential benefit of the ALS community.

Learn more about ALS and the therapeutic unmet need we strive to fill: https://bit.ly/4aITwgv